Urology News and Research

Latest Urology News and Research

PN kidney cancer surgery not being used for older, sicker and poorer uninsured patients

An increasingly common and safer type of surgery for kidney cancer is not as likely to be used for older, sicker and poorer patients who are uninsured or rely on Medicare or Medicaid for their health care, according to a new study by researchers at Henry Ford Hospital.

16 May 2012

Association between gender and surgical outcomes of kidney removal not well understood

Women do better than men after surgical removal of part or all of a cancerous kidney, with fewer post-operative complications, including dying in the hospital, although they are more likely to receive blood transfusions related to their surgery.

16 May 2012

First study to compare complication rates after RAPN and LPN

Robot-assisted surgery has replaced another minimally invasive operation as the main procedure to treat kidney cancer while sparing part of the diseased organ, and with comparable results, according to a new research study by Henry Ford Hospital urologists.

16 May 2012

CAPE arrests growth of prostate cancer tumors

Could it be that a remedy from thousands of years ago holds the secret to stopping prostate cancer? A newly published study furthers the exploration of caffeic acid phenethyl ester (CAPE) and its potential anticarcinogen and antioxidant properties. The demonstrated ability of CAPE to stop prostate cancer tumors from growing may soon have it earning a spot among other natural remedies for prostate cancer treatment.

11 May 2012

Shire, Cosmo and Giuliani International file suit against Watson over generic Lialda

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Mesalamine Delayed-release Tablets, 1.2g. Watson's ANDA product is a generic version of Shire Development LLC's Lialda.

10 May 2012

Poor women and African Americans with ovarian cancer less likely to receive care

Poor women and African Americans with ovarian cancer are less likely to receive the highest standards of care, leading to worse outcomes than among white and affluent patients, according to a study of 50,000 women presented by UC Irvine's Dr. Robert Bristow at the Society of Gynecologic Oncology's annual meeting March 27.

9 May 2012

Domain Surgical's FMwand successfully used in 100 cases

Domain Surgical, a leading developer of advanced thermal surgical technology, today announced that its novel FMwand Ferromagnetic Surgical System has been used successfully in 100 cases. The FMwand simultaneously cuts and coagulates tissue without passing electrical current into the patient, making it safe to use near delicate tissue structures.

9 May 2012

Screening younger men at risk of prostate cancer can reduce metastatic cancer and deaths

Screening younger men and men at risk of prostate cancer can be beneficial in reducing metastatic cancer and deaths and should not be abandoned, states an article published in CMAJ (Canadian Medical Association Journal).

8 May 2012

Johnson & Johnson announces acquisition of Bioseal

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

3 May 2012

ArthroCare first quarter total revenue increases 5.6% to $92.9 million

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced its financial results for the first quarter ended March 31, 2012.

3 May 2012

Watson first quarter net income increases 87% to $208.8 million

Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

Best and worst paid doctors: Survey

More and more U.S. doctors are regretting their career choices. According to an annual survey of physician pay called Physician Compensation Survey from Medscape/WebMD this is in spite of the hefty amounts that they make each year. However the survey reveals that some specialities may earn more than others.

29 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

Watson enters definitive agreement to acquire Actavis

Watson Pharmaceuticals, Inc. and Actavis Group today jointly announced that Watson has entered into a definitive agreement to acquire privately held Actavis for approximately EUR4.25 billion upfront.

27 Apr 2012

Doctor claims to have found the elusive G spot

In an article published Wednesday by the Journal of Sexual Medicine, the semi-retired Florida gynecologist declared that he had found it. For his study he conducted a postmortem examination of an 83-year-old woman in Warsaw Medical University's Department of Forensic Medicine. Unlike the United States, which strictly regulates the research use of cadavers, Poland allows the dissection of human remains soon after death, when fine distinctions in tissue remain easy to see.

26 Apr 2012

Robot assisted laparoscopic radical prostatectomy better than other surgical techniques

Outcomes from use of a robot to assist surgeons in removal of a cancerous prostate are at least as good, if not better, than the other two techniques used for a radical prostatectomy -- open or laparoscopic surgery -- according to a large meta analysis led by researchers at NewYork-Presbyterian/Weill Cornell.

26 Apr 2012

PLUS Diagnostics, MDxHealth partner to co-promote ConfirmMDx for Prostate Cancer

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, and PLUS Diagnostics today announced that they have entered into an agreement to co-promote MDxHealth's ConfirmMDx for Prostate Cancer test in the United States.

26 Apr 2012

Prostate cancer screening recommendations not heeded by 44% men: Survey

81-year-old billionaire Warren Buffett was diagnosed with prostate cancer after having the finding initially detected through a screening blood test to measure a cancer marker called prostate specific antigen or PSA.

25 Apr 2012

NCH opens first suburban ambulatory surgery center

Nationwide Children's Hospital has opened its first suburban ambulatory surgery center. Located in Westerville, Ohio, the center is an extension of the current surgical services on the main campus, one that gives families an option for convenient access to a full spectrum of pediatric outpatient surgical services.

25 Apr 2012